HomeBUSINESS
BUSINESS

Mitsubishi Tanabe’s Half-Year Sales Up 4.5%, but Profits Dip on Radicava Promotion Costs
(Nov.2.2017)

Mitsubishi Tanabe Pharma achieved a 4.5% rise in sales in the first half of FY2017 through March, lifted by positive sales of core products in Japan and the US launch of the amyotrophic lateral sclerosis (ALS) drug Radicava (edaravone) in August ...
(LOG IN FOR FULL STORY)

News Calendar